These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 36207167)

  • 1. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
    Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
    J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
    Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
    Harding L; Zhdanava M; Shah A; Pesa J; Totev TI; Tardif-Samson A; Pilon D; Joshi K
    Curr Med Res Opin; 2024 Sep; 40(9):1615-1623. PubMed ID: 39034772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.
    Teeple A; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Joshi K
    Curr Med Res Opin; 2023 Aug; 39(8):1167-1174. PubMed ID: 37492015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
    Olfson M; Amos TB; Benson C; McRae J; Marcus SC
    J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.
    Samalin L; Mekaoui L; De Maricourt P; Sauvaget A; Codet MA; Gaudré-Wattinne É; Wicart C; Rothärmel M
    Int J Psychiatry Clin Pract; 2024 Jun; 28(2):83-93. PubMed ID: 39223855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
    Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH
    World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
    Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
    JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
    Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
    Canuso CM; Ionescu DF; Li X; Qiu X; Lane R; Turkoz I; Nash AI; Lopena TJ; Fu DJ
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):516-524. PubMed ID: 34412104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.